Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Extina Foam in Seborrheic Dermatitis
NCT00703846Phase 4Completed
- Sponsor
- GSK
- Start
- Jun 2008
- Primary completion
- Apr 2010
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of ketoconazole in seborrheic dermatitis (SD), sponsored by GSK. Primary endpoint: Number of Participants With Any Adverse Event at 52 weeks. Started Jun 2008; status: completed.
02
Drugs
ketoconazole
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on NCT00703846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00703846.